Related Experiment Video
Updated: Jun 20, 2026
12:41
Multiparametric Tumor Organoid Drug Screening Using Widefield Live-Cell Imaging for Bulk and Single-Organoid Analysis
Published on: December 23, 2022
5.1K
Harnessing Organoid Platforms for Nanoparticle Drug Development
Linanni Chen1,2,3,4, Xinying Luo1,2,3,4, Jiankang Zhang1,2,3,4
1College of Science, Mathematics and Technology, Wenzhou-Kean University, Wenzhou, Zhejiang, People's Republic of China.
Drug Design, Development and Therapy
|July 23, 2025
Summary
Tumor organoids offer a superior preclinical model for cancer nanomedicine by replicating human tumor complexity and the tumor microenvironment (TME). This approach enhances the reliability of nanodrug evaluation, accelerating clinical translation.
Area of Science:
- Biomedical Engineering
- Oncology
- Drug Delivery Systems
Background:
- Clinical translation of cancer nanomedicine is limited by inadequate preclinical models.
- Existing models fail to capture tumor microenvironment (TME) dynamics and patient variability.
- This leads to unreliable predictions of nanodrug efficacy and safety.
Purpose of the Study:
- To introduce tumor organoids as an advanced preclinical model for cancer nanomedicine.
- To demonstrate the utility of organoids in evaluating nanodrug delivery, efficacy, and safety.
- To highlight organoids' potential for personalized medicine and improved preclinical success rates.
Main Methods:
- Development and utilization of three-dimensional tumor organoid cultures.
- Characterization of organoids for architectural, molecular, and TME fidelity.
- Application of organoids to assess nanodrug performance in pancreatic, breast, and glioblastoma cancer models.
- Establishment of organoid biobanks for large-scale drug screening.
Main Results:
- Tumor organoids accurately recapitulate native tumor architecture and TME interactions.
- Organoids provide reliable assessments of nanodrug delivery efficiency and therapeutic effects.
- Demonstrated efficacy in evaluating nanodrug safety profiles across diverse cancer types.
- Organoid biobanks enable rapid screening and identification of tailored treatment strategies.
Conclusions:
- Tumor organoids represent a significant advancement over conventional preclinical models in cancer nanomedicine.
- The organoid-driven approach overcomes critical limitations in tumor modeling.
- This paradigm accelerates the development and clinical translation of effective nanotherapies.
